Abstract | INTRODUCTION:
Fish oil has been shown to reduce serum triglyceride (TG) concentrations. In HIV-infected patients on antiretroviral therapy, high TG concentrations likely contribute to increased risk of cardiovascular disease. AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone. METHODS: RESULTS: Median baseline TG was 662 mg/dL in the fish oil group and 694 mg/dL in the fenofibrate group (P = not significant). Fish oil reduced TG levels by a median of 283 mg/dL (46%), fenofibrate reduced them by 367 mg/dL (58%), and combination therapy reduced them by 65.5%. Combination therapy achieved TG levels of < or =200 mg/dL in 22.7% subjects. Fish oil had no measurable effect on immunologic parameters or the pharmacokinetics of lopinavir. CONCLUSIONS:
|
Authors | John G Gerber, Douglas W Kitch, Carl J Fichtenbaum, Robert A Zackin, Stéphannie Charles, Evelyn Hogg, Edward P Acosta, Elizabeth Connick, David Wohl, E Milu Kojic, Constance A Benson, Judith A Aberg |
Journal | Journal of acquired immune deficiency syndromes (1999)
(J Acquir Immune Defic Syndr)
Vol. 47
Issue 4
Pg. 459-66
(Apr 01 2008)
ISSN: 1525-4135 [Print] United States |
PMID | 17971707
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Fish Oils
- Hypolipidemic Agents
- Triglycerides
- Fenofibrate
|
Topics |
- Adult
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Drug Therapy, Combination
- Female
- Fenofibrate
(therapeutic use)
- Fish Oils
(therapeutic use)
- HIV Infections
(blood, complications, drug therapy)
- Humans
- Hypertriglyceridemia
(blood, complications, drug therapy)
- Hypolipidemic Agents
(therapeutic use)
- Male
- Middle Aged
- Time Factors
- Treatment Outcome
- Triglycerides
(blood)
|